Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody –Drug Conjugate
AbstractSmall cell lung cancer (SCLC) comprises about 15% of all cases of lung cancer. In recent years, owing to a change in the epidemiology of smoking habits, the incidence of the tumor has decreased; however, it remains a significant challenge to global health. While the tumor has a favorable initial response to chemoradiation, relapse is invariable, and second-line regimens may be intolerable given the severity of side effects. For patients with tumors resistant to second-line regimens, no current standard regimens exist. Rovalpituzumab tesirine is a novel antibody –drug conjugate, targeting delta-like protein 3, fun...
Source: Drugs in R&D - September 19, 2018 Category: Drugs & Pharmacology Source Type: research
Critical Review of the Use of Second-Generation Antipsychotics in Obsessive –Compulsive and Related Disorders
AbstractCurrently, all second-generation antipsychotics are approved for schizophrenia. Many are also approved for bipolar disorder, with some also approved as adjunctive treatment for depression and autism-related irritability. Second-generation antipsychotics are increasingly being prescribed for indications other than those approved by the Food and Drug Administration, such as in dementia, anxiety, and post-traumatic stress disorder to name a few. Obsessive –compulsive and related disorders are a group of disorders characterized by preoccupation and repetitive behaviors. According to the latest edition of the Diagnost...
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
ConclusionsFindings from this study indicate that intravenous golimumab is effective in managing RA in a population of patients switching directly from infliximab (mean last dose 7.4 mg/kg). (Source: Drugs in R&D)
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
Evaluation of Cardiovascular Disease Risk in HIV-1 –Infected Patients Treated with Darunavir
ConclusionsThis comprehensive review of Janssen-sponsored clinical trial, post-marketing, and epidemiological data does not suggest that CVD should be considered an important risk for users of darunavir. (Source: Drugs in R&D)
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers
ConclusionsThis compartmental modelling analysis suggests ELF exposures of both ceftazidime and avibactam exceed levels required for efficacy in plasma. (Source: Drugs in R&D)
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
Comments on: “In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea”
(Source: Drugs in R&D)
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
Risks and Benefits of Sodium Polystyrene Sulfonate for Hyperkalemia in Patients on Maintenance Hemodialysis
ConclusionsOur results indicate that Na-resin exhibited an advantage in treating hyperkalemia when used in small amounts. However, when prescribing an ion-exchange resin at a higher dose, physicians should select the type and amount of resin according to the sodium and/or calcium load in each case. (Source: Drugs in R&D)
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment
ConclusionOur data show that prulifloxacin is a safe quinolone and is well tolerated in both subjects with normal renal function and patients with impaired renal function, requiring a minimal dosage adjustment only in patients with severe renal impairment. (Source: Drugs in R&D)
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
Correction to: Evaluation of Cardiovascular Disease Risk in HIV ‑1–Infected Patients Treated with Darunavir
In the original publication of the article, Table 2 has been published incorrectly. (Source: Drugs in R&D)
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
Octreotide Use in Neonates: A Case Series
ConclusionOctreotide was used safely as an adjunctive therapy for the treatment of chylothorax and chylous ascites in neonates. However, larger prospective controlled trials are required to establish the optimal dose, time of initiation, duration and efficacy of octreotide therapy in neonates. (Source: Drugs in R&D)
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
Correction to: Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication
In the Original Publication. (Source: Drugs in R&D)
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
Critical Review of the Use of Second-Generation Antipsychotics in Obsessive –Compulsive and Related Disorders
AbstractCurrently, all second-generation antipsychotics are approved for schizophrenia. Many are also approved for bipolar disorder, with some also approved as adjunctive treatment for depression and autism-related irritability. Second-generation antipsychotics are increasingly being prescribed for indications other than those approved by the Food and Drug Administration, such as in dementia, anxiety, and post-traumatic stress disorder to name a few. Obsessive –compulsive and related disorders are a group of disorders characterized by preoccupation and repetitive behaviors. According to the latest edition of the Diagnost...
Source: Drugs in R&D - August 31, 2018 Category: Drugs & Pharmacology Source Type: research
New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment
ConclusionOur data show that prulifloxacin is a safe quinolone and is well tolerated in both subjects with normal renal function and patients with impaired renal function, requiring a minimal dosage adjustment only in patients with severe renal impairment. (Source: Drugs in R&D)
Source: Drugs in R&D - August 27, 2018 Category: Drugs & Pharmacology Source Type: research
Risks and Benefits of Sodium Polystyrene Sulfonate for Hyperkalemia in Patients on Maintenance Hemodialysis
ConclusionsOur results indicate that Na-resin exhibited an advantage in treating hyperkalemia when used in small amounts. However, when prescribing an ion-exchange resin at a higher dose, physicians should select the type and amount of resin according to the sodium and/or calcium load in each case. (Source: Drugs in R&D)
Source: Drugs in R&D - August 10, 2018 Category: Drugs & Pharmacology Source Type: research
